HIGHLY SENSITIVE IMMUNOCONJUGATE, PREPARING METHOD THEREOF, IN VITRO DIAGNOSTIC REAGENT AND IN VITRO DIAGNOSTIC KIT INCLUDING THE SAME

Abstract

Disclosed are a highly sensitive immunoconjugate, and an in vitro reagent and an in vitro diagnostic kit including the same, in which binding specificity with a target substrate is increased and a detection signal is amplified, thereby improving largely the sensitivity, accuracy and reproducibility of detection.

Claims

1. A highly sensitive immunoconjugate comprising: a) a first nanoparticle immunoconjugate including a first nanoparticle-DNA conjugate and a first antibody-DNA conjugate, wherein a DNA fragment included in the first nanoparticle-DNA conjugate and a DNA fragment included in the first antibody-DNA conjugate are complementarily linked to each other; and b) a second nanoparticle immunoconjugate including a second nanoparticle-DNA conjugate and a second antibody-DNA conjugate, wherein a DNA fragment included in the second nanoparticle-DNA conjugate and a DNA fragment included in the second antibody-DNA conjugate are complementarily linked to each other.

2. The highly sensitive immunoconjugate of claim 1, wherein the first antibody specifically binds to a part of a target substance and the second antibody specifically binds to the other part of the target substance.

3. The highly sensitive immunoconjugate of claim 1, wherein the DNA fragment included in the first nanoparticle-DNA conjugate has a complementary binding force with a DNA probe immobilized in a biochip.

4. The highly sensitive immunoconjugate of claim 1, wherein the surface of each of the first nanoparticle and the second nanoparticle includes at least one functional group of an amine group (—NH.sub.2), a carboxyl group (—COOH) or an aldehyde group (—COH).

5. The highly sensitive immunoconjugate of claim 1, wherein the first nanoparticle and the second nanoparticle are latex beads.

6. The highly sensitive immunoconjugate of claim 5, wherein the latex bead has a diameter of 100 to 500 nm.

7. The highly sensitive immunoconjugate of claim 1, wherein the second nanoparticle contains a fluorescent material.

8. The highly sensitive immunoconjugate of claim 1, wherein 15,000 to 40,000 DNA fragments bind to each of the first nanoparticle and the second nanoparticle.

9. A preparing method of a highly sensitive immunoconjugate comprising the steps of: (i) preparing a first nanoparticle-DNA conjugate and a second nanoparticle-DNA conjugate; (ii) preparing a first antibody-DNA conjugate and a second antibody-DNA conjugate; and (iii) preparing a first nanoparticle immunoconjugate and a second nanoparticle immunoconjugate in which a DNA fragment included in the first nanoparticle-DNA conjugate and a DNA fragment included in the first antibody-DNA conjugate are complementarily linked to each other and a DNA fragment included in the second nanoparticle-DNA conjugate and a DNA fragment included in the second antibody-DNA conjugate are complementarily linked to each other.

10. The preparing method of the highly sensitive immunoconjugate of claim 9, wherein in the first nanoparticle-DNA conjugate and the second nanoparticle-DNA conjugate, an NH.sub.2 group of a terminal of the DNA fragment binds to a carboxyl group of the surface of each of the first nanoparticle and the second nanoparticle.

11. An in vitro diagnostic reagent including the highly sensitive immunoconjugate of claim 1.

12. An in vitro diagnostic kit including the highly sensitive immunoconjugate of claim 1.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0031] The above and other aspects, features and other advantages of the present invention will be more clearly understood from the following detailed description taken in conjunction with the accompanying drawings, in which:

[0032] FIG. 1 is a schematic diagram illustrating a highly sensitive immunoconjugate according to an embodiment of the present disclosure;

[0033] FIG. 2A is a schematic diagram illustrating a preparing method of a first antibody-DNA conjugate according to an embodiment of the present disclosure;

[0034] FIG. 2B is a schematic diagram illustrating a preparing method of a second antibody-DNA conjugate according to an embodiment of the present disclosure;

[0035] FIG. 3 is a schematic diagram illustrating a preparing method of an antibody-fluorescence immunoconjugate according to an embodiment of the present disclosure;

[0036] FIG. 4 is a schematic diagram illustrating an operational principle of an in vitro diagnostic kit including a highly sensitive immunoconjugate according to an embodiment of the present disclosure;

[0037] FIG. 5A is a schematic diagram illustrating a detection method using an enzyme-linked immunosorbent assay (ELISA) according to an embodiment of the present disclosure;

[0038] FIG. 5B illustrates a measurement concentration range of Troponin T of the ELISA according to an embodiment of the present disclosure;

[0039] FIG. 6A is a schematic diagram illustrating a fluorescence-linked immunosorbent assay (FLISA) using a primary immunoconjugate according to an embodiment of the present disclosure;

[0040] FIG. 6B illustrates a measurement concentration range of Troponin T of the FLISA using the primary immunoconjugate according to an embodiment of the present disclosure;

[0041] FIG. 7A is a schematic diagram illustrating a FLISA using a secondary (highly sensitive) immunoconjugate according to an embodiment of the present disclosure; and

[0042] FIG. 7B illustrates a measurement concentration range of Troponin T of the FLISA using the secondary (highly sensitive) immunoconjugate according to an embodiment of the present disclosure.

[0043] FIG. 8 is a schematic diagram illustrating a non-specific binding that occurs in ELISA and FLISA of the prior art.

[0044] FIG. 9 is a schematic diagram illustrating that DNA immobilized on a solid substrate and an antibody-DNA conjugate are combined through a DNA-DNA reaction.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

[0045] Before describing the present disclosure in detail, terms or words used in this specification should not be construed as unconditionally limited to a conventional or dictionary meaning, and the inventors of the present disclosure can appropriately define and use the concept of various terms in order to describe their invention in the best method. Furthermore, it should be understood that these terms or words should be interpreted as meanings and concepts consistent with the technical idea of the present disclosure.

[0046] That is, the terms used in this specification are only used to describe a preferred embodiment of the present disclosure, and are not intended to specifically limit the contents of the present disclosure, and it should be noted that these terms are terms defined in consideration with various possibilities of the present disclosure.

[0047] In addition, in this specification, it should be understood that the singular expression may include a plural expression unless clearly indicated in another meaning in the context, and even if similarly expressed in the plural, the singular expression may include the meaning of the singular number.

[0048] Throughout this specification, when a component is described as “including” the other component, the component does not exclude any other component, but may further include any other component unless otherwise indicated in contrary.

[0049] Further, hereinafter, in the following description of the present disclosure, a detailed description of a configuration determined to unnecessarily obscure the subject matter of the present disclosure, for example, known technologies including the related arts may be omitted.

[0050] Hereinafter, the present disclosure will be described in more detail.

[0051] The present disclosure is to develop a method of binding antibody-DNA conjugates linked with antibody-DNA to a 9 G DNA solid substrate immobilized with genes through DNA-DNA reaction, instead of a method of directly immobilizing antibody proteins on the solid substrate in order to solve a nonspecific problem occurring in low-concentration protein analysis in measurement methods based on ELISA and FLISA of the related arts (FIG. 9).

[0052] As such, since the 9 G DNA substrate consisting of a DNA monomolecular layer has a hydrophilic surface, there is no nonspecific binding to other proteins, and since the antibody binding to the DNA of the solid substrate is also an antibody-DNA conjugate linked to the gene, there is no nonspecificity by the protein, so that low-concentration protein analysis is possible.

[0053] However, there is still a part to be solved in addition to the protein nonspecific problem to be established as an analysis system that accurately reproduces a very low concentration of biomarker material present in a sample.

[0054] In order to accurately detect the low concentration, a fluorescent marker used as an analysis marker needs to represent a stable and strong signal, but a single fluorescent molecule has limitations on a measurement method due to fluorescence signal intensity, fluorescent half-life, and the like, and technological development of new signal amplification capable of overcoming these disadvantages is required.

[0055] For signal-amplification technologies capable of increasing detection sensitivity by amplifying the analysis signal, the present inventors prepared an immunoconjugate including nanoparticles capable of very accurately measuring and analyzing traces of proteins and an in vitro diagnostic reagent and an in vitro diagnostic kit including the same.

[0056] Meanwhile, fluorescent nanoparticles have sizes of 1 micrometer or less unlike general phosphors having sizes of dozens of micrometers and exhibit different properties from single phosphors due to various effects occurring in a nano scale due to an increase in surface area/volume ratio according to the size. The fluorescent nanoparticles have features such as excellent thermal and chemical stability, excellent photostability, and high fluorescent intensity, and the like as compared with existing other fluorescent materials.

[0057] Under this underground, the present inventors prepared a highly sensitive immunoconjugate and an in vitro diagnostic reagent and an in vitro diagnostic kit including the same by binding biomarkers such as antibodies, genes, and the like with fluorescent nanoparticles by using fluorescent nanoparticles capable of compensating for the disadvantages of single fluorescent molecules as a medium, in order to develop a method capable of effectively detecting a target substance even if a smaller amount of sample is used by amplifying a fluorescent signal of a fluorescent immunodiagnostic kit.

[0058] Highly Sensitive Immunoconjugate and Preparing Method Thereof

[0059] A highly sensitive immunoconjugate of the present disclosure includes a) a first nanoparticle immunoconjugate including a first nanoparticle-DNA conjugate and a first antibody-DNA conjugate, wherein DNAs of the first nanoparticle-DNA conjugate and the first antibody-DNA conjugate are complementarily linked to each other; and b) a second nanoparticle immunoconjugate including a second nanoparticle-DNA conjugate and a second antibody-DNA conjugate, wherein DNAs of the second nanoparticle-DNA conjugate and the second antibody-DNA conjugate are complementarily linked to each other.

[0060] A preparing method of the highly sensitive immunoconjugate of the present disclosure includes the steps of (i) preparing a first nanoparticle-DNA conjugate and a second nanoparticle-DNA conjugate, (ii) preparing a first antibody-DNA conjugate and a second antibody-DNA conjugate; and (iii) preparing a first nanoparticle immunoconjugate and a second nanoparticle immunoconjugate in which DNA fragments of the first nanoparticle-DNA conjugate and the first antibody-DNA conjugate are complementarily linked to each other and DNA fragments of the second nanoparticle-DNA conjugate and the second antibody-DNA conjugate are complementarily linked to each other.

[0061] The highly sensitive immunoconjugate of the present disclosure includes the first nanoparticle immunoconjugate and the second nanoparticle immunoconjugate.

[0062] The first nanoparticle immunoconjugate includes the first nanoparticle-DNA conjugate and the first antibody-DNA conjugate, wherein the DNA fragments of the first nanoparticle-DNA conjugate and the first antibody-DNA conjugate may be complementarily linked to each other.

[0063] The first antibody may specifically bind to a part of the target substance and the second antibody may specifically bind to the other part of the target substance.

[0064] <First Nanoparticle-DNA Conjugate>

[0065] In the first nanoparticle-DNA conjugate, DNA fragments bind to a first nanoparticle.

[0066] The first nanoparticles are preferably latex beads or latex particles as microsperes. The latex beads may be formed from an amorphous polymer such as polystyrene as spherical particles with a colloidal size. Because of a method of arranging polystyrene chains to the beads, since the surface is very hydrophobic, the latex beads are an ideal material to adsorption of a material such as proteins.

[0067] On the surface of the nanoparticle, a variety of surface modifications may be used to bind various molecules and proteins to the bead surface. The surface of the nanoparticle may include any one functional group of an amine group (—NH.sub.2), a carboxyl group (—COOH) or an aldehyde group (—COH). For example, the nanoparticle illustrated in FIG. 1 consists of a polystyrene microsphere as a carboxyl latex including a carboxyl group on a particle surface.

[0068] In addition, an amine latex consists of a polystyrene microsphere and includes an amine group on the particle surface. Functional groups of the particle surface may be used for co-binding with components of genes, antigens, and antibodies. The size of the latex bead may be used with a diameter of 20 to 1000 nm, and preferably a diameter of 100 to 500 nm.

[0069] 15,000 to 40,000 DNA fragments may bind to the nanoparticle.

[0070] Referring to FIG. 1, a NH.sub.2-DNA fragment binds to a carboxyl group on the nanoparticle surface to form a nanoparticle-DNA conjugate. Accordingly, although not illustrated in FIG. 1, 15,000 or more of DNA fragments may be bound in the nanoparticle-DNA conjugate.

[0071] Accordingly, in the highly sensitive immunoconjugate according to the present disclosure, the detection sensitivity is increased by 100 times or more compared to the conventional ELISA, and the detection sensitivity is increased by 10 times or more compared to a single fluorescent immunoconjugate.

[0072] <First Antibody-DNA Conjugate>

[0073] In the first antibody-DNA conjugate, DNA fragments bind to a first antibody.

[0074] Referring to FIG. 2A, a first antibody-DNA conjugate is formed by binding a first antibody-SH to a SMCC-DNA fragment for the first antibody which is prepared by chemical bond of an NH.sub.2-DNA fragment for the first antibody and sulfo-SMCC. The DNA fragment of the first SMCC-DNA fragment may be an oligonucleotide with a size of 30 to 40 mer.

[0075] The first antibody is an immunoglobulin which specifically binds to a target biomolecule for purification, detection, and measurement of a target substance.

[0076] The target substance includes all biomolecules such as a specific protein, an autoantibody, a viral phage, a nucleic acid molecule aptamer, hapten (DNP), and the like, and further, is not particularly limited to the detailed description.

[0077] <First Nanoparticle Immunoconjugate>

[0078] Referring to FIG. 1, the first nanoparticle-DNA conjugate and the first antibody-DNA conjugate bind to each other to form the first nanoparticle immunoconjugate. The DNA fragments of the first nanoparticle-DNA conjugate and the first antibody-DNA conjugate include complementary sequences with each other to be hybridized and linked to each other. For example, the first NH.sub.2-DNA fragment (the DNA fragment included in the first nanoparticle-DNA conjugate of FIG. 1) and the first SMCC-DNA fragment (the DNA fragment included in the first antibody-DNA conjugate of FIG. 1) of Table 2 have complementary base sequences with each other.

[0079] <Second Nanoparticle-DNA Conjugate>

[0080] Referring to FIG. 1, the second nanoparticle-DNA conjugate may be prepared by the same preparing method as the first nanoparticle-DNA conjugate, except that the second nanoparticle is a fluorescent latex and except for the sequences of the DNA fragments.

[0081] The second nanoparticle is preferably a fluorescent latex containing a fluorescent material. The second nanoparticle may contain various fluorescent dyes therein. A fluorescence wavelength may use various fluorescences, such as (Ex/Em): Blue(365/415), Yellow-green(505/515), Nile red (535/575), Orange (540/560), Red-orange (565/580), Red(580/605), Crimson (625/645), Dark red (660/680), and Infrared (715/755). The material, the functional groups of the surface, the size, and the like of the second nanoparticle are duplicated with those described in the first nanoparticle, and will be omitted.

[0082] <Second Antibody-DNA Conjugate>

[0083] In the second antibody-DNA conjugate, DNA fragments bind to a second antibody.

[0084] Referring to FIG. 2B, the preparing method of the second antibody-DNA conjugate may be the same as the preparing method of the first antibody-DNA conjugate, except for the sequences of the DNA fragments and the antibody.

[0085] The second antibody is immunoglobulin that specifically binds to a target biomolecule for purification, detection, and measurement of the target substance, and immunoglobulin that specifically binds to a different site from a site where the first antibody binds to a specific protein.

[0086] The target substance includes all biomolecules such as a specific protein, an autoantibody, a viral phage, a nucleic acid molecule aptamer, hapten (DNP), and the like, and further, is not particularly limited to the detailed description.

[0087] In the present disclosure, the first antibody specifically binds to a part of the target substance and the second antibody specifically binds to the other part of the target substance. Referring to FIG. 4 or 7A, the first antibody specifically binds to a part of one target substance and the second antibody binds to the other part of the same target substance. The target substance may be a target protein to be detected, but is not limited thereto.

[0088] <Second Nanoparticle Immunoconjugate>

[0089] Referring to FIG. 1, the second antibody-DNA conjugate (prepared in FIG. 2) complementarily binds to the second nanoparticle-DNA conjugate in which a second NH.sub.2-DNA fragment binds to a carboxyl group of the surface of the second nanoparticle to form the second nanoparticle immunoconjugate.

[0090] The DNA fragments of the second nanoparticle-DNA conjugate and the second antibody-DNA conjugate include complementary sequences with each other to be hybridized and linked to each other. For example, the second NH.sub.2-DNA fragment (the DNA fragment included in the second nanoparticle-DNA conjugate of FIG. 1) and the second SMCC-DNA fragment (the DNA fragment included in the second antibody-DNA conjugate of FIG. 2) of Table 2 have complementary base sequences with each other.

[0091] <Highly Sensitive Immunoconjugate>

[0092] The highly sensitive immunoconjugate of the present disclosure is prepared by combining the first nanoparticle immunoconjugate and the second nanoparticle immunoconjugate.

[0093] Referring to FIG. 7A, when the highly sensitive immunoconjugate of the present disclosure reacts with a specimen, a primary antibody and a secondary antibody bind to antigens in the specimen, and when this mixture flows on a biochip immobilized with a DNA probe, the DNA fragment of the nanoparticle binding to the first antibody complementarily binds to the DNA probe (DNA-DNA bond) and a signal is detected by a fluorescent nanoparticle linked to the second antibody. Since 15,000 to 40,000 DNA fragments may bind to the first nanoparticle and the second nanoparticle, the fluorescent signal is amplified to detect a target substance with high sensitivity. Referring to the following Examples, in the highly sensitive immunoconjugate according to the present disclosure, the detection sensitivity is increased by 100 times or more compared to the conventional ELISA, and the detection sensitivity is increased by 10 times or more compared to a single fluorescent immunoconjugate (see FIG. 6A).

[0094] In Vitro Diagnostic Reagent

[0095] The present disclosure provides an in vitro diagnostic reagent including the highly sensitive immunoconjugate.

[0096] The in vitro diagnostic reagent according to the present disclosure may further include a material which is commonly used in the art of the present disclosure. Particularly, the in vitro diagnostic reagent may further include a reaction buffer for an antigen-antibody reaction, a washing buffer used for washing after the reaction, and the like, but is not limited thereto.

[0097] In Vitro Diagnostic Kit

[0098] The present disclosure provides an in vitro diagnostic kit including the highly sensitive immunoconjugate.

[0099] The in vitro diagnostic kit according to the present disclosure may further include a device and a material which are commonly used in the art of the present disclosure. Particularly, the in vitro diagnostic kit may further include a biochip to which 9 guanines (9 G) technique is applied, and a lateral flow using the fluorescence immunoassay is preferable, but is not limited thereto.

[0100] As an example of the in vitro diagnostic kit according to the present disclosure, referring to FIG. 4, the in vitro diagnostic kit includes a diagnostic strip including at least two or more test lines and a diagnostic kit body receiving the diagnostic strip. The diagnostic strip includes a sample pad into which a specimen including a target substance is injected, a first test line which is connected to the sample pad and immobilized with a first probe gene to which a first highly sensitive immunoconjugate specifically binds, and a second test line which is immobilized with a second probe gene to which a second highly sensitive immunoconjugate specifically binds. The second test line includes a glass fiber detection film fixed to a position spaced apart from the first test line.

[0101] Here, on the glass fiber detection film, the first test lien and the second test line are sequentially formed based on the sample pad side.

[0102] In addition, the diagnostic strip may further include an absorption pad which is attached to a support part while sequentially connected to the detection film and in which the remaining specimen passing through the detection film is absorbed.

[0103] In a diagnostic strip in a wide-range in vitro diagnostic kit applicable to various target substances, two or more test lines (DNA probes) specifically binding to the same target substance in the specimen are provided, so that quantification of the target substance in the specimen may be performed with high reliability even if the in vitro diagnosis is performed using a low concentration of specimen.

[0104] In the diagnostic strip in the in vitro diagnostic kit, two or more test lines specifically binding to the same target substance in the specimen are provided, so that a concentration range of the specimen capable of accurate quantification may be widely applied from a low concentration to a high concentration.

[0105] The vitro diagnostic kit according to the present disclosure may be widely applied to various diagnostics, such as pregnancy diagnosis, cardiovascular disease diagnosis, inflammation diagnosis, cancer diagnosis, and the like.

EXAMPLES

[0106] Hereinafter, the present disclosure will be described in detail with reference to Examples for specific description. However, Examples according to the present disclosure may be modified in various forms, and it is not interpreted that the scope of the present disclosure is limited to the following Examples.

[0107] Examples of the present disclosure will be provided for more completely explaining the present disclosure to those skilled in the art.

[0108] In the following Preparation Examples, Comparative Examples, Examples, and drawings, a ‘primary immunoconjugate’ means a combination of an antibody-DNA conjugate and an antibody-fluorescence conjugate and a ‘secondary immunoconjugate’ or ‘highly sensitive immunoconjugate’ means a combination of a first nanoparticle immunoconjugate and a second nanoparticle immunoconjugate.

[0109] <Materials>

[0110] Materials used in immunoconjugates of the following Preparation Examples and Examples were shown in Table 1 and DNA sequences used in the immunoconjugates were shown in Table 2.

TABLE-US-00001 TABLE 1 Item Base sequence and feature First nanopartiole Microspere, latex bead or latex particle (latex ) Second nanoparticle Microspere, fluorescent bead or fluorescent (fluorescence) particle First antibody Antibody binding to first part of specific protein as primary antibody Second antibody Antibody binding to second part of specific protein as primary antibody

TABLE-US-00002 TABLE 2 Base Sequence Item and feature Size NH.sub.2-DNA fragment NH.sub.2-TTTATATTTATACCT 26 for first antibody TGCGAGCGCGG NH.sub.2-DNA fragment NH.sub.2-TTTATATTTTGGCCA 26 for second antibody CACTGTCCATT SMCC-DNA fragment SMCC-TTTATATTTCCGCG 26 for first antibody CTCGCAAGGTAT SMCC-DNA fragment SMCC-TTTATATTTAATGG 26 for second antibody ACAGTGTGGCCA

<Preparation Example 1> Antibody-DNA Conjugate

[0111] FIGS. 2A and 2B illustrate schematic diagrams of preparing methods of a first antibody-DNA conjugate and a second antibody-DNA conjugate, and the preparing methods of the first antibody-DNA conjugate and the second antibody-DNA conjugate were the same as each other. Referring to FIGS. 2A and 2B, the antibody-DNA conjugate was prepared by preparing SMCC-DNA from NH.sub.2-DNA (Step 1), introducing an —SH functional group to the antibody (Step 2), and forming the antibody-DNA conjugate by reaction of SMCC-DNA and antibody-SH (Step 3).

<Preparation Example 1.1> Preparation of SMCC-DNA

[0112] ##STR00001##

[0113] 100 μl of NH.sub.2-DNA (35 nmol) and 10 μl of sulfo-SMCC (10 mg/ml) were put in a 1.5 ml tube and reacted at room temperature for 1 hour. After the reaction, the remaining non-reacted sulfo-SMCC was removed through Sephadex LH20 column purification and only the SMCC-DNA was obtained to confirm the concentration.

<Preparation Example 1.2> Preparation of Antibody-SH

[0114] ##STR00002##

[0115] 100 μl of an antibody (0.5 mg) and 1 mg of 2-iminothiolane powder were put in a tube and reacted at room temperature for 1 hour. After the reaction with the antibody-SH, the remaining iminothiolane was separated through a Sephadex LH20 column and the concentration of the antibody-SH obtained through the column was confirmed.

<Preparation Example 1.3> Preparation of Antibody-DNA Conjugate

[0116] ##STR00003##

[0117] 100 μl of 1×PBS was put in a tube added with the SMCC-DNA fragment prepared in Preparation Example 1.1 and vortex-mixed, and then the antibody-SH prepared in Preparation Example 1.2 was added at a ratio of 1:1. After reaction at room temperature for 30 minutes, the mixture was purified through a Sephadex LH20 column to obtain an antibody-DNA conjugate.

<Preparation Example 2> Nanoparticle Immunoconjugate

[0118] FIG. 1 illustrates a schematic diagram of a preparing method of a nanoparticle immunoconjugate, and the preparing methods of the first nanoparticle immunoconjugate and the second nanoparticle immunoconjugate were the same as each other and there was a difference only in that the second nanoparticle was a fluorescent latex. Referring to FIG. 1, the nanoparticle immunoconjugate was prepared by preparing a nanoparticle-DNA conjugate (Step 1) and reacting the antibody-DNA conjugate prepared in Preparation Example 1 with the nanoparticle-DNA conjugate (Step 2).

<Preparation Example 2.1> Preparation of First Nanoparticle-DNA Conjugate

[0119] ##STR00004##

[0120] 100 μl of a 2% nanoparticle and NH.sub.2-DNA (20 nmole, 50 μl) were put in a tube and added with 200 μl of an MES buffer. 50 μl of EDC (200 mg/ml) was added and reacted at room temperature for 2 hours. After centrifugation at 13,000 rpm, a supernatant was removed to obtain a nanoparticle-DNA conjugate in a pellet form.

<Preparation Example 2.2> Preparation of First Nanoparticle Immunoconjugate

[0121] ##STR00005##

[0122] The first nanoparticle-DNA conjugate of Preparation Example 2.1 was dispersed in 1 ml of 1×PBS and vortexed, and then added with the first antibody-DNA conjugate (the DNA fragments of the first antibody-DNA conjugate and the first nanoparticle-DNA conjugate had the complementary sequences) prepared in Preparation Example 1 and reacted at room temperature for 30 minutes.

<Preparation Example 2.3> Preparation of Second Nanoparticle Immunoconjugate

[0123] Except for using a fluorescent latex as the second nanoparticle and the sequences of the DNA fragments and the antibody, Preparation Example 2.3 was performed in the same manner as Preparation Examples 2.1 and 2.2.

<Example 1> Primary Immunoconjugate

[0124] The antibody-DNA conjugate prepared in Preparation Example 1 and the antibody-fluorescence immunoconjugate prepared in FIG. 3 were mixed at 1:1 and used.

<Example 2> Secondary (Highly Sensitive) Immunoconjugate

[0125] The first nanoparticle immunoconjugate prepared in Preparation Example 2.2 and the second nanoparticle immunoconjugate prepared in Preparation Example 2.3 were mixed at 1:1 and used as a secondary (highly sensitive) immunoconjugate.

<Comparative Example 1> Detection of Troponin T by ELISA

[0126] Human Cardiac Troponin T in the blood was detected by ELISA using an antibody-enzyme immunoconjugate. The ELISA was performed by the ELISA method illustrated in FIG. 5A.

[0127] Coating of Troponin T Capture Antibody

[0128] 1) A troponin T capture antibody was prepared at a concentration (1 to 10 μg/mL) using a carbonate/bicarbonate buffer (pH 9.6) and then dispensed in a PVC microtiter plate. 2) The plate cover was closed and the plate was incubated at 4° C. for 12 hours. 3) The coating solution was removed and the plate was washed with 200 μL of PBS twice. 4) The plate was swept to remove the remaining washing solution. 5) The remaining solution was carefully removed with a paper towel.

[0129] Blocking and Sample Injection

[0130] 1) In order to block remaining protein-binding sites, 200 μL of a blocking buffer (5% non-fat dry milk/PBS) was added to each well of a coated well plate. 2) The well plate was incubated at room temperature for 2 hours. 3) Samples #1 to #7 were added in the well plate by 100 μL, respectively, and a sample for standards curve was added in the well plate by 100 μL. 4) The samples were incubated at 37° C. for 90 min (an unknown sample was always compared with Standard Curve). 5) The samples were removed and washed with 200 μL of PBS three times.

[0131] Incubation for Secondary Antibody and Detection

[0132] 1) 100 μL of a diluted secondary antibody was added in each well. 2) It was confirmed whether the secondary antibody was linked to a different site from the capture antibody for a target protein. 3) The plate cover was closed and the well plate was incubated at room temperature for 2 hours. 4) The washing process was performed with PBS four times. 5) A detection antibody diluted with a blocking buffer was added in the well by 100 μdi. 6) The plate cover was closed and the well plate was incubated at room temperature for 2 hours. 7) The washing process was performed with PBS four times.

[0133] Detection

[0134] By using Horse Radish Peroxidase (HRP) as an enzyme for detection, the absorbance of a detection antibody-HRP immunoconjugate was measured. A TMB (3,3′,5,5′-tetramethylbenzidine) solution was added to each well by 200 μl, incubated at room temperature for 30 minutes, and then added with 200 μl of a static solution (2 MH.sub.2SO.sub.4), and the absorbance of 450 nm was measured.

[0135] FIG. 5B illustrates a result of detecting cardiac Troponin T in a human blood sample by the ELISA method. Referring to FIG. 5B, it can seen that the measured cardiac troponin T concentration is shown in a detection range of 10 ng/ml (10,000 pg/ml) or more to about 1000 ng/ml in a high concentration area.

<Experimental Example 1> Detection of Troponin T Using Primary Immunoconjugate

[0136] Troponin T was detected by a method of FIG. 6A using the primary immunoconjugate prepared in Example 1. 1) Blood plasma samples #1 to #7 were put in a microtube by 10 μl, respectively. 2) 100 μl of a primary immunoconjugate solution (mixture of primary immunoconjugate and antibody-fluorescence immunoconjugate) was incubated at room temperature for 10 minutes. 3) 60 μl of an R buffer was added and 170 μl of the mixture was deployed in a lateral flow membrane strip for 10 minutes. 4) 170 μl of a washing solution was added and the mixture was washed for 10 minutes. 5) The membrane strip was scanned by a membrane strip dedicated scanner (BMT 1D Scanner) and then the troponin T was detected.

[0137] FIG. 6B is a result of detecting cardiac Troponin T in a human blood sample by lateral flow immunofluorescence assay using the primary immunoconjugate. Referring to FIG. 6B, it was confirmed that the measured cardiac troponin T concentration was shown in a detection range of 90 pg/ml to 2400 pg/ml in a high concentration area and the LOD was increased 10 times or more as compared with existing antibody-enzyme conjugate type of ELISA.

<Experimental Example 2> Detection of Troponin T Using Secondary (Highly Sensitive) Immunoconjugate

[0138] Troponin T was detected by a method of FIG. 7A using the secondary (highly sensitive) immunoconjugate prepared in Example 2. 1) Blood plasma samples #1 to #7 were put in a microtube by 10 μl, respectively. 2) 100 μl of a secondary immunoconjugate solution was added and incubated at room temperature for 10 minutes. 3) 60 μl of an R buffer was added and 170 μl of the mixture was deployed in a lateral flow membrane strip for 10 minutes. 4) 170 □μl of a washing solution was added and the mixture was washed for 10 minutes. 5) The membrane strip was scanned by a membrane strip dedicated scanner (BMT 1D Scanner) and then the troponin T was detected.

[0139] FIG. 7B is a result of detecting cardiac Troponin T in a human blood sample by lateral flow immunofluorescence assay using the secondary (highly sensitive) immunoconjugate. Referring to FIG. 7B, it was confirmed that the measured cardiac troponin T concentration was shown in a detection range of 1.2 pg/ml to 80 pg/ml in a low concentration area and the detection LOD was increased 100 times or more as compared with existing antibody-enzyme conjugate type of ELISA.

[0140] As described above, the detailed embodiments for the highly sensitive immunoconjugate according to the present disclosure, the preparing method thereof, and the in vitro diagnostic reagent and the in vitro diagnostic kit including the same had been described, but it will be apparent that various modifications can be made without departing from the scope of the present disclosure.

[0141] Therefore, the scope of the present disclosure should not be limited to the embodiments and should be defined by the appended claims and equivalents to the appended claims.

[0142] In other words, the embodiments described above are illustrative in all aspects and should be understood as not being restrictive, and the scope of the present disclosure is represented by appended claims to be described below rather than the detailed description, and it is to be interpreted that the meaning and scope of the appended claims and all changed or modified forms derived from the equivalents thereof are included within the scope of the present disclosure.

EXPLANATION OF SEQUENCE LISTING

[0143] SEQ ID NO: 1 is a sequence of a DNA fragment included in a first nanoparticle-DNA conjugate according to an embodiment of the present disclosure.

[0144] SEQ ID NO: 2 is a sequence of a DNA fragment included in a second nanoparticle-DNA conjugate according to an embodiment of the present disclosure.

[0145] SEQ ID NO: 3 is a sequence of a DNA fragment included in a first antibody-DNA conjugate according to an embodiment of the present disclosure.

[0146] SEQ ID NO: 4 is a sequence of a DNA fragment included in a second antibody-DNA conjugate according to an embodiment of the present disclosure.